• 1

    World Health Organization, 2001. Buruli ulcer. Management of Mycobacterium ulcerans disease. Available at: http://www.whqlibdoc.who.int/hq/2001/WHO_CDS_CPE_GBUI_2001.3.pdf. Accessed August 26, 2008.

  • 2

    van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K, 1999. Mycobacterium ulcerans infection. Lancet 354 :1013–1018.

  • 3

    World Health Organization, 2008. Buruli ulcer: progress report, 2004–2008. Wkly Epidemiol Rec 17 :145–156.

  • 4

    Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, Asiedu K, Addy J, 2002. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 8 :167–170.

    • Search Google Scholar
    • Export Citation
  • 5

    Wansbrough-Jones M, Phillips R, 2006. Buruli ulcer: emerging from obscurity. Lancet 367 :1849–1858.

  • 6

    Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM, 1999. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 353 :986.

    • Search Google Scholar
    • Export Citation
  • 7

    Portaels F, Meyers WM, Ablordey A, Castro AG, 2008. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2 :e178.

    • Search Google Scholar
    • Export Citation
  • 8

    Pszolla N, Sarkar MR, Strecker W, Kern P, Kinzl L, Meyers WM, Portaels F, 2003. Buruli ulcer: a systemic disease. Clin Infect Dis 37 :e78–e82.

    • Search Google Scholar
    • Export Citation
  • 9

    Stienstra Y, Dijkstra PU, Guédénon A, Johnson RC, Ampadu EO, Mensah T, Klutse EY, Etuaful S, Deepak S, van der Graaf WT, van der Werf TS, 2004. Development of a questionnaire assessing Buruli ulcer-induced functional limitation. Am J Trop Med Hyg 70 :318–322.

    • Search Google Scholar
    • Export Citation
  • 10

    Stienstra Y, Dijkstra PU, van Wezel MJ, van Roest MH, Beets M, Zijlstra I, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, Van der Graaf WT, Van der Werf TS, 2005. Reliability and validity of the buruli ulcer functional limitation score questionnaire. Am J Trop Med Hyg 72 :449–452.

    • Search Google Scholar
    • Export Citation
  • 11

    Stienstra Y, van Roest MHG, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, van der Graaf WT, van der Werf TS, 2005. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health 10 :1251–1257.

    • Search Google Scholar
    • Export Citation
  • 12

    World Health Organization, 2004. Provisional guidance on the role of antibiotics in the management of Mycobacterium ulcerans disease. Available at: http://www.who.int/entity/buruli/information/antibiotics/en/. Accessed August 26, 2008.

  • 13

    Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M, 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49 :3182–3186.

    • Search Google Scholar
    • Export Citation
  • 14

    World Health Organization, 2001. Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. Available at: http://whqlibdoc.who.int/hq/2001/WHO_CDS_CPE_GBUI_2001.4.pdf. Accessed August 26, 2008.

  • 15

    Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson W, Klutse E, Crofts K, Massavon W, Etuaful S, Thompson R, Asamoah-Opare K, Racz P, Vloten F, van Berberich C, Kruppa T, Ampadu E, Fleischer B, Adjei O, 2007. A step-wise approach to the laboratory diagnosis of Buruli ulcer disease. Trop Med Int Health 12 :89–96.

    • Search Google Scholar
    • Export Citation
  • 16

    Gerhardt JJ, Rondinelli RD, 2001. Goniometric techniques for range-of-motion assessment. Phys Med Rehabil Clin N Am 12 :507–527.

  • 17

    World Health Organization, 2007. Summary report of the WHO annual meeting on Buruli Ulcer, 2–4 April 2007 and report of the technical advisory Group (TAG) meeting, 5 April, Geneva, 2007. Available at: http://www.who.int/buruli/events/Report_2007_meeting_FINAL.pdf. Accessed August 26, 2008.

  • 18

    World Health Organization, 2008. Meeting of the WHO technical advisory group on Buruli ulcer 3 April 2008, Geneva, summary report. Available at: http://www.who.int/buruli/events/TAG_report_FINAL.pdf. Accessed August 26, 2008.

  • 19

    SAS Institute, 2006. SAS 9.1.3. SAS Institute, Cary, NC.

  • 20

    Bretzel G, Siegmund V, Racz P, van Vloten F, Ngos F, Thompson W, Biason P, Adjei O, Fleischer B, Nitschke J, 2005. Post-surgical assessment of excised tissue from patients with Buruli ulcer disease: progression of infection in macroscopically healthy tissue. Trop Med Int Health 10 :1199–1206.

    • Search Google Scholar
    • Export Citation
  • 21

    Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J, 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents 51 :4029–4035.

    • Search Google Scholar
    • Export Citation
  • 22

    Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F, 2005. Buruli ulcer recurrence, Benin. Emerg Infect Dis 11 :584–589.

  • 23

    Kanga JM, Kacou DE, Sangaré A, Dabila Y, Asse NH, Djakeaux S, 2003. [Recurrence cases observed after surgical treatment of Buruli ulcer in Cote d’Ivoire]. Bull Soc Pathol Exot 96 :406–409.

    • Search Google Scholar
    • Export Citation
  • 24

    Teelken MA, Stienstra Y, Ellen DE, Quarshie E, Klutse E, van der Graaf WT, van der Werf TS, 2003. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 88 :51–56.

    • Search Google Scholar
    • Export Citation
  • 25

    Amofah G, Asamoah S, Afram-Gyening C, 1998. Effectiveness of excision of preulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 28 :81–83.

    • Search Google Scholar
    • Export Citation
  • 26

    World Health Organization, 2004. Buruli ulcer disease. Wkly Epidemiol Rec 79 :145–149.

  • 27

    World Health Organization, 2006. Buruli ulcer: a manual on how to prevent disability. Available at: http://www.who.int/buruli/information/publications/pod/en/index.html. Accessed August 26, 2008.

  • 28

    Asiedu K, Etuaful S, 1998. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 59 :1015–1022.

  • 29

    Ellen DE, Stienstra Y, Teelken MA, Dijkstra PU, van der Graaf WT, van der Werf TS, 2003. Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Trop Med Int Health 8 :90–96.

    • Search Google Scholar
    • Export Citation
  • 30

    Phanzu DM, Bafende EA, Dunda BK, Imposo DB, Kibadi AK, Nsiangana SZ, Singa JN, Meyers WM, Suykerbuyk P, Portaels F, 2006. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002–2004. Am J Trop Med Hyg 75 :311–314.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Outcome of Patients with Buruli Ulcer after Surgical Treatment with or without Antimycobacterial Treatment in Ghana

View More View Less
  • 1 Department of Infectious Diseases and Tropical Medicine (DITM), Ludwig-Maximilians University of Munich, Munich, Germany; Agogo Presbyterian Hospital, Agogo, Ghana; Dunkwa Governmental Hospital, Dunkwa-on-Offin, Ghana; Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany; Kumasi Centre for Collaborative Research and Tropical Medicine (KCCR), Kwame Nkrumah University of Science and Technology Kumasi, Ghana

This study assesses the frequency of recurrences and treatment outcome after surgery of buruli ulcer disease (BUD) with or without concomitant antimycobacterial treatment. Of 129 laboratory-confirmed BUD patients who underwent surgery in two treatment centers in Ghana, 79 (61%) were retrieved for follow-up 4–29 months after the initial treatment. Among 7 (9%) recurrent cases no significant association was found between recurrences and clinical or treatment specific factors including antimycobacterial treatment. In 21 (27%) patients, a reduced range of motion (ROM) of one or more joints was detected. Lesions other than nodules, joint involvement, and skin grafting were identified as independent risk factors. Functional limitations hampering daily activities were perceived by 22% of the patients. Compared with other studies the recurrence rate was relatively low, functional limitations were, however, frequent. This emphasizes the need for improvement of pre- and post-treatment wound care as well as rehabilitation programs.

Save